Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice

4. marts 2019 opdateret af: Amgen

Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice

The objective of this prospective, observational study in Czech Republic and Slovakia is to describe per country the characteristics of women treated with denosumab in routine clinical practice and the clinical management of these patients during the first 2 years of treatment. In addition, the study aims to collect safety data in the real-life clinical practice settings on adverse drug reactions (ADRs) and serious ADRs.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

600

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Slovakiet
      • Banska Bystrica, Slovakiet, 974 01
        • Research Site
      • Bratislava, Slovakiet, 826 06
        • Research Site
      • Bratislava, Slovakiet, 833 05
        • Research Site
      • Humenne, Slovakiet, 066 01
        • Research Site
      • Kosice, Slovakiet, 040 01
        • Research Site
      • Kosice-Saca, Slovakiet, 040 15
        • Research Site
      • Lubochna, Slovakiet, 034 91
        • Research Site
      • Lucenec, Slovakiet, 984 01
        • Research Site
      • Martin, Slovakiet, 036 01
        • Research Site
      • Nitra, Slovakiet, 949 01
        • Research Site
      • Presov, Slovakiet, 080 01
        • Research Site
      • Trnava, Slovakiet, 917 75
        • Research Site
      • Zilina, Slovakiet, 010 01
        • Research Site
  • Tjekkiet
      • Brno, Tjekkiet, 602 00
        • Research Site
      • Brno, Tjekkiet, 638 00
        • Research Site
      • Ceske Budejovice, Tjekkiet, 370 01
        • Research Site
      • Havlickuv Brod, Tjekkiet, 580 22
        • Research Site
      • Karlovy Vary, Tjekkiet, 367 17
        • Research Site
      • Kutna Hora, Tjekkiet, 284 01
        • Research Site
      • Ostrava, Tjekkiet, 702 00
        • Research Site
      • Ostrava-Trebovice, Tjekkiet, 722 00
        • Research Site
      • Plzen, Tjekkiet, 323 00
        • Research Site
      • Praha 11, Tjekkiet, 148 00
        • Research Site
      • Praha 2, Tjekkiet, 128 50
        • Research Site
      • Praha 4 - Nusle, Tjekkiet, 140 00
        • Research Site
      • Trutnov, Tjekkiet, 541 21
        • Research Site
      • Vsetin, Tjekkiet, 755 01
        • Research Site
      • Zlin, Tjekkiet, 760 01
        • Research Site
      • Zlin, Tjekkiet
        • Osteocentrum Zlin

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

The study was conducted at various study centers in the Czech Republic and Slovakia. Postmenopausal women with osteoporosis who receive an injection of denosumab and meet the inclusion/exclusion criteria will be eligible to participate in the study.

Beskrivelse

Inclusion Criteria

  • Women with a clinical diagnosis of postmenopausal osteoporosis
  • Decision has been made to treat with denosumab 60 mg once every 6 months
  • Have received their first injection of denosumab within 8 weeks prior to enrolling in this study.
  • Appropriate written informed consent has been obtained (as required per local country regulations)

Exclusion Criteria

  • Participating in ongoing or have participated in previous denosumab clinical trials
  • Participation in other clinical or device trials in the last 6 months
  • Contra-indicated for treatment with Prolia® according to the approved applicable local product label.
  • Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Denosumab
Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.
Biologisk: Denosumab
This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
Andre navne:
  • Prolia®

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants Receiving All Prescriptions and Injections of Denosumab From the Initial Prescribing Physician's Office
Tidsramme: 24 months
Number of participants who received all injection(s), including baseline injection, from the initial prescribing site irrespective of total number of injections received on study.
24 months
Number of Participants Receiving an Individual Prescription and Injection of Denosumab From the Initial Prescribing Physician Office by Each Individual Injection
Tidsramme: Baseline (day 1), and at Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively)
Baseline (day 1), and at Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively)
Number of Participants Receiving All Prescriptions and Injections of Denosumab
Tidsramme: Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively)
Number of participants receiving all prescriptions and injections of denosumab whether or not the injections are given at the initial prescribing physician's office.
Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively)
Number of Participants With a Referral by the Prescribing Physician to Other Health Care Providers for Continuation or Follow-up of Care
Tidsramme: 24 months
24 months
Types of Health Care Providers Administering an Individual Injection of Denosumab at the Baseline Injection
Tidsramme: Baseline (day 1)
Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the baseline injection.
Baseline (day 1)
Types of Health Care Providers Administering Denosumab at the First Post-baseline Injection
Tidsramme: Month 6
Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the first post-baseline injection.
Month 6
Types of Health Care Providers Administering Denosumab at the Second Post-baseline Injection
Tidsramme: Month 12
Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the second post-baseline injection.
Month 12
Types of Health Care Providers Administering Denosumab at the Third Post-baseline Injection
Tidsramme: Month 18
Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the third post-baseline injection.
Month 18
Types of Health Care Providers Administering Denosumab at the Fourth Post-baseline Injection
Tidsramme: Month 24
Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the fourth post-baseline injection.
Month 24
Number of Denosumab Post-baseline Injections Received by Each Participant
Tidsramme: 24 months
24 months
Number of Participants Having Radiologic Bone Assessments
Tidsramme: Pre-baseline (before first denosumab injection) and during the study (post-baseline)
Number of participants having radiologic bone assessments pre-treatment with denosumab and during the study.
Pre-baseline (before first denosumab injection) and during the study (post-baseline)
Number of Participants Having Osteoporosis Related Laboratory Examinations
Tidsramme: Pre-baseline (before first denosumab injection) and post-baseline
Number of participants having osteoporosis related laboratory examinations pre-treatment with denosumab and during the study. Participants may not have been given denosumab injection when they attended each visit.
Pre-baseline (before first denosumab injection) and post-baseline

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Adverse Drug Reactions (ADRs) to Denosumab
Tidsramme: 24 months
Adverse events (AEs) that were considered related to denosumab as evaluated by the investigator were classified as adverse drug reactions (ADRs).
24 months
Number of Participants With Serious ADRs to Denosumab
Tidsramme: 24 months
Serious adverse events that were considered related to denosumab were classified as serious adverse drug reactions (SADRs). A serious adverse event (SAE) is any AE that also: • is fatal • is life threatening (places the patient at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • is an "other significant medical hazard" that does not meet any of the above criteria.
24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Amgen

Samarbejdspartnere

One Amgen Center Drive
THOUSAND OAKS
CA
91320-1799
USA

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. juni 2012

Primær færdiggørelse (Faktiske)

15. maj 2015

Studieafslutning (Faktiske)

15. maj 2015

Datoer for studieregistrering

Først indsendt

26. juli 2012

Først indsendt, der opfyldte QC-kriterier

26. juli 2012

Først opslået (Skøn)

30. juli 2012

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. marts 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. marts 2019

Sidst verificeret

1. marts 2019

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 20110132

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Osteoporose, postmenopausal

Kliniske forsøg med Denosumab

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Lebanon

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner